Previous studies have indicated that the disappointing results of TGF-β inhibitors in clinical trials are largely related to the inhibition of TGF-β in regulatory T cells, which exacerbates autoimmune disease (7). The gene discussed is TGFB1; the disease is autoimmune disease.